Approximately 15%-20% of patients with breast cancer (BC) have tumors that overexpress human epidermal growth factor 2 (HER2), or HER2-positive BC,1-3 which is associated with an aggressive clinical phenotype and a historically poor prognosis. Here, ERBB2 is linked to breast carcinoma.